{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:48:27Z","timestamp":1789069707251,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) represent a continuous spectrum of a glomerular disease driven by dysregulation of the complement and characterized by C3 deposition alone or associated with immunoglobulins. Despite the significant burden and poor prognosis associated with these conditions, no therapies have been approved for their treatment in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observational study, we present three pediatric cases that span the clinical and pathogenic spectrum of C3G\/IC-MPGN, including multi-resistant nephrotic syndrome with clear terminal pathway activation, familial genetic C3G with early anti-C3 intervention, and multi-resistant nephrotic syndrome of unclear etiology, likely related to IC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All three patients were successfully treated with the C3\/C3b inhibitor pegcetacoplan, that inhibited C3, blocked C3 consumption, and restored physiological C3 levels, leading to significant proteinuria reduction within the first month. After six months, patients experienced notable improvements in kidney function, a complete remission of nephrotic syndrome, and normalized proteinuria levels. There were no treatment-related adverse events, only mild infections that resolved with standard oral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support the potential of C3 inhibition with pegcetacoplan in pediatric patients with refractory or genetic C3G.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                    <jats:p>A higher resolution version of the Graphical abstract is available as Supplementary information.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-025-07092-7","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:04:18Z","timestamp":1765209858000},"page":"1351-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pegcetacoplan in idiopathic and familial pediatric C3 glomerulopathy"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4942-3883","authenticated-orcid":false,"given":"Elena","family":"Rom\u00e1n Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"S\u00e1ez Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Reparaz Suevos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Perez Ebri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Aguilar Bacallado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"LLopis Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Climente Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Rodriguez de C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"7092_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D\u2019Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fr\u00e9meaux-Bacchi V, Gale DP, de Goicoechea Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, de Rodr\u00edguez C\u00f3rdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT (2013) C3 glomerulopathy: consensus report. Kidney Int 84:1079\u20131089. https:\/\/doi.org\/10.1038\/ki.2013.377","journal-title":"Kidney Int"},{"key":"7092_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101331","volume":"45","author":"K Kaartinen","year":"2019","unstructured":"Kaartinen K, Safa A, Kotha S, Ratti G, Meri S (2019) Complement dysregulation in glomerulonephritis. Semin Immunol 45:101331. https:\/\/doi.org\/10.1016\/j.smim.2019.101331","journal-title":"Semin Immunol"},{"key":"7092_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2020.00205","volume":"8","author":"A Mastrangelo","year":"2010","unstructured":"Mastrangelo A, Serafinelli J, Giani M, Montini G (2010) Clinical and pathophysiological insights into immunological mediated glomerular diseases in childhood. Front Pediatr 8:1\u201322. https:\/\/doi.org\/10.3389\/fped.2020.00205","journal-title":"Front Pediatr"},{"key":"7092_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12500","volume":"274","author":"D Ricklin","year":"2016","unstructured":"Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD (2016) Complement component C3 - the \u201cSwiss Army Knife\u201d of innate immunity and host defense. Immunol Rev 274:33\u201358. https:\/\/doi.org\/10.1111\/imr.12500","journal-title":"Immunol Rev"},{"key":"7092_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith RJH, Appel GB, Blom AM et al (2019) C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 15:129\u2013143","journal-title":"Nat Rev Nephrol"},{"key":"7092_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ekir.2023.12.007","volume":"16","author":"B Tarragon Estebanez","year":"2023","unstructured":"Tarragon Estebanez B, Bomback AS (2023) C3 glomerulopathy: novel treatment paradigms. Kidney Int Rep 16:569\u2013579. https:\/\/doi.org\/10.1016\/j.ekir.2023.12.007","journal-title":"Kidney Int Rep"},{"key":"7092_CR7","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.3390\/ijms25168698","volume":"25","author":"R Horneff","year":"2024","unstructured":"Horneff R, Czech B, Yeh M, Surova E (2024) Three years on: the role of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH) since its initial approval. Int J Mol Sci 25:8698. https:\/\/doi.org\/10.3390\/ijms25168698","journal-title":"Int J Mol Sci"},{"key":"7092_CR8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024qdwvz5bg","volume":"35","author":"CM Nester","year":"2024","unstructured":"Nester CM, Bomback AS, Ariceta Iraola MG et al (2024) VALIANT: a randomized, multicenter, double-blind, placebo (PBO)-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). J Am Soc Nephrol 35:10S","journal-title":"J Am Soc Nephrol"},{"key":"7092_CR9","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","volume":"25","author":"BP Dixon","year":"2023","unstructured":"Dixon BP, Greenbaum LA, Huang L, Rajan S, Ke C, Zhang Y, Li L (2023) Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases. Kidney Int Rep 25:2284\u20132293. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.033","journal-title":"Kidney Int Rep"},{"key":"7092_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","volume":"10","author":"AS Bomback","year":"2025","unstructured":"Bomback AS, Daina E, Remuzzi G et al (2025) Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis. Kidney Int Rep 10:87\u201398","journal-title":"Kidney Int Rep"},{"key":"7092_CR11","unstructured":"Vivarelli M, Ariceta G, Borovitz Y, Dixon BP, Greenbaum LA, Licht C, Mastrangelo A, Melhem N, Fujita N, Van de Kar NCAJ, Wallace D, Li L, L\u00f3pez L\u00e1zaro L, Szamosi J, Nester CM (2025) Pegcetacoplan for adolescents with C3G or primary IC-MPGN: VALIANT phase 3 double-blind placebo-controlled trial subgroup analysis [poster no. P-456]. 20th IPNA Congress 19\u201323, Cape Town, South Africa"},{"key":"7092_CR12","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00467-025-06673-w","volume":"40","author":"MC Mancuso","year":"2025","unstructured":"Mancuso MC, Cugno M, Griffini S, Grovetti E, Nittoli T, Mastrangelo A, Tedesco F, Montini G, Ardissino G (2025) Efficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy. Pediatr Nephrol 40:1959\u20131963. https:\/\/doi.org\/10.1007\/s00467-025-06673-w","journal-title":"Pediatr Nephrol"},{"key":"7092_CR13","unstructured":"Vivarelli M et al (2025) Pegcetacoplan for adolescents with C3G or IC-MPGN in phase 3 VALIANT. 3rd annual spring clinical meetings of the national kidney foundation 9\u201313, Boston, MA"},{"key":"7092_CR14","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","volume":"15","author":"V Fr\u00e9meaux-Bacchi","year":"2008","unstructured":"Fr\u00e9meaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 15:4948\u20134952. https:\/\/doi.org\/10.1182\/blood-2008-01-133702","journal-title":"Blood"},{"key":"7092_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","volume":"36","author":"P Khandelwal","year":"2021","unstructured":"Khandelwal P, Bhardwaj S, Singh G, Sinha A, Hari P, Bagga A (2021) Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. Pediatr Nephrol 36:591\u2013600. https:\/\/doi.org\/10.1007\/s00467-020-04736-8","journal-title":"Pediatr Nephrol"},{"key":"7092_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00467-024-06587-z","volume":"40","author":"A Cappoli","year":"2025","unstructured":"Cappoli A, Kersnik-Levart T, Silecchia V, Ariceta G, Gjerstad AC, Ghiggeri G, Haffner D, Kanzelmeyer N, Levtchenko E, Pasini A, Waters A, Aguilera JCL, Peruzzi L, Noris M, Bresin E, Gargiulo A, Emma F, Vivarelli M (2025) C3 glomerulopathy in children: a European longitudinal study evaluating outcome. Pediatr Nephrol 40:979\u2013986. https:\/\/doi.org\/10.1007\/s00467-024-06587-z","journal-title":"Pediatr Nephrol"},{"key":"7092_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","volume":"72","author":"M Le Quintrec","year":"2018","unstructured":"Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Fr\u00e9meaux-Bacchi V, Fakhouri F (2018) Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72:84\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2017.11.019","journal-title":"Am J Kidney Dis"},{"key":"7092_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00467-020-04768-0","volume":"36","author":"Z Zahir","year":"2021","unstructured":"Zahir Z, Wani AS, Gupta A, Agrawal V (2021) Pediatric C3 glomerulopathy: a 12-year single-center experience. Pediatr Nephrol 36:601\u2013610. https:\/\/doi.org\/10.1007\/s00467-020-04768-0","journal-title":"Pediatr Nephrol"},{"key":"7092_CR19","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.ekir.2020.09.019","volume":"3","author":"A Kirpalani","year":"2020","unstructured":"Kirpalani A, Jawa N, Smoyer WE, Licht C, Midwest Pediatric Nephrology Consortium (2020) Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children. Kidney Int Rep 3:2313\u20132324. https:\/\/doi.org\/10.1016\/j.ekir.2020.09.019","journal-title":"Kidney Int Rep"},{"key":"7092_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00467-021-05221-6","volume":"37","author":"MAHM Michels","year":"2022","unstructured":"Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ (2022) Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol 37:601\u2013612. https:\/\/doi.org\/10.1007\/s00467-021-05221-6","journal-title":"Pediatr Nephrol"},{"key":"7092_CR21","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.4103\/jfmpc.jfmpc_831_21","volume":"10","author":"AK Shukla","year":"2021","unstructured":"Shukla AK, Jhaj R, Misra S, Ahmed SN, Nanda M, Chaudhary D (2021) Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care 10:3303\u20133308. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_831_21","journal-title":"J Family Med Prim Care"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07092-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07092-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:03:10Z","timestamp":1774299790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07092-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7092"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07092-7","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Hospital Universitario Dr. Peset, proceedings 048\/25.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that they have obtained consent from the patients discussed in the report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"All the authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}